Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Frovatriptan

Drug Profile

Frovatriptan

Alternative Names: Allegro; Auradol; EN 3266; Frova; Frovatriptan succinate; Isimig; Migard; Pitunal; Rilamig; SB 209509; SB 209509AX; VML 251

Latest Information Update: 16 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Endo Pharmaceuticals; Menarini; SK Chemicals; Teva Neuroscience; Vernalis
  • Class Antimigraines; Carbazoles; Small molecules; Tryptamines
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Migraine
  • Preregistration Submission Withdrawal Menstrual migraine

Most Recent Events

  • 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
  • 12 May 2016 First Generic equivalent available in USA for Migraine (PO)
  • 06 Aug 2011 Registered for Migraine in Russia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top